Literature DB >> 24469337

Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide.

Amit N Vora1, Thomas Gehrig, Thomas M Bashore, Todd L Kiefer.   

Abstract

A 75-year old woman with a history of coronary disease status post 3-vessel coronary artery bypass grafting (CABG) 8 years ago and a repeat one-vessel CABG 2 years ago in the setting of aortic valve replacement with a #19 mm St. Jude bileaflet mechanical valve for severe aortic stenosis presented with two to three weeks of progressive dyspnea and increasing substernal chest discomfort. Echocardiography revealed a gradient to 31 mmHg across her aortic valve, increased from a baseline of 13 mmHg five months previously. Fluoroscopy revealed thrombosis of her mechanical aortic valve. She was not a candidate for surgery given her multiple comorbidities, and fibrinolysis was contraindicated given a recent subdural hematoma 1 year prior to presentation. She was treated with heparin and eptifibatide and subsequently demonstrated resolution of her aortic valve thrombosis. We report the first described successful use of eptifibatide in addition to unfractionated heparin for the management of subacute valve thrombosis in a patient at high risk for repeat surgery or fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469337     DOI: 10.1007/s11239-014-1055-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  8 in total

Review 1.  Mechanical heart valve prostheses: identification and evaluation.

Authors:  Jagdish Butany; Manmeet S Ahluwalia; Craig Munroe; Cristina Fayet; Christina Ahn; Patrick Blit; Charis Kepron; Roberto J Cusimano; Richard L Leask
Journal:  Cardiovasc Pathol       Date:  2003 Jan-Feb       Impact factor: 2.185

2.  2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce W Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Rick A Nishimura; Blase A Carabello; David P Faxon; Michael D Freed; Bruce W Lytle; Patrick T O'Gara; Robert A O'Rourke; Pravin M Shah
Journal:  J Am Coll Cardiol       Date:  2008-09-23       Impact factor: 24.094

Review 3.  Antiplatelet and anticoagulation for patients with prosthetic heart valves.

Authors:  David R Massel; Stephen H Little
Journal:  Cochrane Database Syst Rev       Date:  2013-07-09

4.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.

Authors:  Y Ikeda; M Handa; K Kawano; T Kamata; M Murata; Y Araki; H Anbo; Y Kawai; K Watanabe; I Itagaki
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 5.  Fluid mechanics of heart valves.

Authors:  Ajit P Yoganathan; Zhaoming He; S Casey Jones
Journal:  Annu Rev Biomed Eng       Date:  2004       Impact factor: 9.590

6.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

7.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.

Authors:  J L Moake; N A Turner; N A Stathopoulos; L H Nolasco; J D Hellums
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

8.  Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Authors:  Robert P Giugliano; Jennifer A White; Christoph Bode; Paul W Armstrong; Gilles Montalescot; Basil S Lewis; Arnoud van 't Hof; Lisa G Berdan; Kerry L Lee; John T Strony; Steven Hildemann; Enrico Veltri; Frans Van de Werf; Eugene Braunwald; Robert A Harrington; Robert M Califf; L Kristin Newby
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.